In the original publication, our report titled ''Alzheimer's disease-associated b-amyloid is rapidly seeded by herpesviridae to protect against brain infection'' by Eimer et al. (2018) (Neuron 99, 56-63, 10.1016 (Neuron 99, 56-63, 10. /j.neuron.2018 .030) contained typographical errors and insufficient methodological details. We are now providing additional methodological details in the online version of the manuscript and correct the following inaccuracies. First, in Figure 1 and accompanying Results section text, the wild type (WT) sample size (n) should be reported as ''n = 9'' and not ''n = 11.'' Second, Figure 1B incorrectly shows a p value (p) of ''p = 0.026.'' The correct value is ''p = 0.013.'' Third, in Method Details under ''AD mouse infection model,'' a volume of 0.2 mL is reported for bilateral injections of herpes simplex virus type I (HSV1) into mouse brain. The correct injection volume is 2 mL. Fourth, all antibodies to herpes glycoproteins were used in experiments at a concentration of 1 mg/mL. Antibodies to herpes glycoprotein B, C, E, H, and G were prepared from 1 mg/mL stocks by a 1:1,000 dilution. Herpes glycoprotein D antibody was prepared by a 1:100 dilution of a 0.1 mg/mL stock solution. Fifth, the three scale bars labeled ''100 nm'' in Figure 4A should read ''200 nm.'' Sixth, the scale bar for Figure 4B should be labeled ''10 mm,'' not ''10 nm.'' Seventh, in Figure S3A , the correct value for the scale bar is ''200 nm,'' not ''50 nm.'' The errors identified here do not alter the report's analysis or conclusions, and these textual corrections, as well as the revised figures, now appear in the online version of this manuscript.
Labeling on Figure 4 was also incorrect. The label ''(a-HSV1)'' in Figures 4B and 4C should read ''(HSV1).'' The legend for Figure 4 has been updated to reflect this change. Additional experimental details have also been added to legend that specify virus/host incubation times: HSV1 was incubated for 48 hr while human herpesvirus 6 viruses (HHV6) were incubated for 72 hr.
Finally, the following paragraph details how virus stocks were prepared, collected, and clarified. This methodology was omitted in the published report.
Viral production and clarification
Viral stocks were produced by the infection of a VERO cell line (CCL-81TM, American Type Culture Collection) for 3 days as described below. VERO cells were grown in complete Dulbecco's modified Eagle medium (DMEM) containing 10% fetal bovine serum (FBS, Atlanta Biologicals), 2 mM L-glutamine, 100 U penicillin, and streptomycin (100 ug/ml) prior to infection. At 90% confluency VERO plates were washed twice with PBS and DMEM containing 2 mM L-glutamine and streptomycin (100 ug/ml) was added. Plates were infected with clarified-HSV1 and incubated for 3 days. The cells are then scraped, freeze thawed through three cycles, and cellular debris is pelleted by a 800 x g spin for 15 minutes. The viral supernatant is pelleted by ultracentrifugation over a 20% sucrose cushion at 22,000 x g for 2 hours. The viral pellet is collected and resuspended in PBS. The viral concentrate is run twice through a 0.22 um filter at 14,000 x g for 15 minutes. The filtrate is collected and aliquots are stored at -72 C.
The expanded, revised STAR Methods section is now corrected online. The authors regret these errors and wish to apologize for any confusion they may have caused.
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